Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maravai Lifesciences Holdings (MRVI) EBT Margin (2020 - 2025)

Maravai Lifesciences Holdings has reported EBT Margin over the past 6 years, most recently at 126.36% for Q4 2025.

  • Quarterly results put EBT Margin at 126.36% for Q4 2025, down 4489.0% from a year ago — trailing twelve months through Dec 2025 was 126.5% (down 2562.0% YoY), and the annual figure for FY2025 was 126.5%, down 2562.0%.
  • EBT Margin for Q4 2025 was 126.36% at Maravai Lifesciences Holdings, down from 108.45% in the prior quarter.
  • Over the last five years, EBT Margin for MRVI hit a ceiling of 885.05% in Q4 2023 and a floor of 249.39% in Q3 2024.
  • Median EBT Margin over the past 5 years was 12.56% (2023), compared with a mean of 22.03%.
  • Biggest five-year swings in EBT Margin: surged 83822bps in 2023 and later crashed -96651bps in 2024.
  • Maravai Lifesciences Holdings' EBT Margin stood at 63.34% in 2021, then dropped by -26bps to 46.83% in 2022, then skyrocketed by 1790bps to 885.05% in 2023, then crashed by -109bps to 81.46% in 2024, then tumbled by -55bps to 126.36% in 2025.
  • The last three reported values for EBT Margin were 126.36% (Q4 2025), 108.45% (Q3 2025), and 156.39% (Q2 2025) per Business Quant data.